Glurenorm (Gliquidone)

Glurenorm (gliquidone) is indicated for the oral treatment of type 2 diabetes mellitus in adults when diet, exercise, and other non‑pharmacologic measures are insufficient to achieve glycemic control.

• Improves fasting and post‑prandial blood glucose levels.
• Can be used as monotherapy or in combination with other oral antidiabetic agents.
• May be considered when patients require a sulfonylurea with a relatively short duration of action.
• Supports long‑term glycemic management as part of a comprehensive diabetes care plan.
• May be prescribed when renal function permits use of sulfonylureas.

The safety profile of Glurenorm reflects the typical effects observed with sulfonylurea medications.

Common

• Mild hypoglycemia, especially if meals are missed.
• Nausea or abdominal discomfort.
• Headache or dizziness.
• Weight gain due to increased insulin activity.

Serious

• Severe hypoglycemia leading to loss of consciousness.
• Allergic reactions such as skin rash, itching, or swelling.
• Hepatic dysfunction indicated by elevated liver enzymes.

Before initiating Glurenorm, clinicians should evaluate several clinical factors to minimize risks and ensure appropriate use.

• Assess renal and hepatic function, as impairment may alter drug clearance.
• Review history of hypoglycemia or sulfonylurea sensitivity.
• Use caution in elderly patients due to increased susceptibility to low blood sugar.
• Monitor blood glucose regularly during dose adjustments.
• Advise patients to maintain consistent meal patterns to prevent hypoglycemia.
• Consider pregnancy and lactation status; the safety profile is not well established.
• Avoid use in patients with known allergy to sulfonylureas.

Glurenorm can interact with other medicines, affecting blood glucose levels or increasing the risk of adverse events.

Avoid

• Concurrent use with other sulfonylureas or insulin, which may cause profound hypoglycemia.
• Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that can raise gliquidone concentrations.
• MAO‑B inhibitors, which may potentiate hypoglycemic effects.

Use with caution

• Beta‑blockers, as they may mask hypoglycemia symptoms.
• Thiazide diuretics, which can increase blood glucose.
• Corticosteroids, which may reduce the drug’s glucose‑lowering efficacy.